Results 61 to 70 of about 8,056 (195)

Combination Therapy With Sintilimab and Anlotinib for Advanced Undifferentiated Pleomorphic Sarcoma: A Case Report and Literature Review

open access: yesClinical Case Reports, Volume 14, Issue 7, July 2026.
ABSTRACT This report describes the case of a 73‐year‐old woman with advanced undifferentiated pleomorphic sarcoma (UPS) who was intolerant to chemotherapy. Following amputation, she received sintilimab plus anlotinib and achieved a partial response with 76.6% tumor reduction.
Yan Chen, Ronghua Chu
wiley   +1 more source

Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma

open access: yes, 2007
Classification of liposarcoma into three biological types encompassing five subtypes, (a) well-differentiated/dedifferentiated, (b) myxoid/round cell, and (c) pleomorphic, based on morphologic features and cytogenetic aberrations, is widely accepted ...
Schwartz, G. K.   +23 more
core   +1 more source

A case of dedifferentiated liposarcoma showing a biphasic pattern on 2-deoxy-2-F18- fluoro-D-glucose positron emission tomography/ computed tomography

open access: yesRare Tumors, 2013
Integrated 2-deoxy-2-F18-fluoro-D-glucose positron emission tomography combined with computed tomography (FDG-PET/CT) has been used in the field of soft tissue sarcoma.
Manabu Hoshi   +4 more
doaj   +1 more source

A living biobank of sarcoma patient‐derived cell cultures reveals multi‐omic and functional insights that capture disease heterogeneity

open access: yesClinical and Translational Medicine, Volume 16, Issue 7, July 2026.
Preclinical models for sarcoma that preserve tumour biology are urgently needed to advance mechanistic understanding and functional precision oncology. 29 early‐passage patient‐derived sarcoma cell (PDC) cultures from 19 patients, representing 11 sarcoma subtypes were established and extensively characterized.
Stefanie Gijsels   +19 more
wiley   +1 more source

Skull Base Surgery in the Pediatric Population—The 2nd International Collaborative Study (1995–2015)

open access: yesHead &Neck, Volume 48, Issue 7, Page 1742-1754, July 2026.
ABSTRACT Background The current study presents the efforts of a global collaborative group to review the management and outcomes of malignant tumors of the skull base in the pediatric population worldwide. Patients and Methods A total of 28 institutions contributed data on 3061 patients. From this, there were 64 pediatric patients (2.1%).
Dan M. Fliss   +50 more
wiley   +1 more source

Systemic Therapy in Metastatic or Unresectable Well-Differentiated/Dedifferentiated Liposarcoma

open access: yes, 2017
Liposarcoma is one of the most common subtypes of soft-tissue sarcoma and consists of three main subtypes, of which well-differentiated liposarcoma and dedifferentiated liposarcoma account for 40–45%.
Charlie D. Zhou   +2 more
core   +1 more source

Advances in Cancer Immunotherapy for Solid Tumors

open access: yesAdvanced Science, Volume 13, Issue 35, 24 June 2026.
Cancer immunotherapy for solid tumors is rapidly evolving beyond classical checkpoint blockade toward more precise strategies. Emerging checkpoint targets, bispecific antibodies, antibody–drug conjugate combinations, personalized vaccines, cellular therapies, and engineered cytokines are expanding therapeutic possibilities, while biomarker‐guided ...
Shira Gabizon‐Peretz   +1 more
wiley   +1 more source

Rare aggressive behavior of MDM2-amplified retroperitoneal dedifferentiated liposarcoma, with brain, lung and subcutaneous metastases

open access: yesRare Tumors, 2016
Dedifferentiated liposarcoma (DDL) is a histologically pleomorphic sarcoma, traditionally defined as well-differentiated liposarcoma with abrupt transition to high grade, nonlipogenic sarcoma.
Imen Ben Salha   +6 more
doaj   +1 more source

Characteristics and Outcomes of Patients With Dedifferentiated Liposarcoma in a US Community Setting

open access: yesCancer Medicine, Volume 15, Issue 6, June 2026.
US community oncology patients with dedifferentiated liposarcoma have heterogeneous profiles, treatments, and outcomes. The poor survival rates in this population suggest an unmet need for better therapeutics. ABSTRACT Introduction Clinical characteristics and outcomes of patients treated for dedifferentiated liposarcoma (DDLPS) at community oncology ...
James E. Butrynski   +10 more
wiley   +1 more source

Survival and prognostic factors among different types of liposarcomas based on SEER database

open access: yesScientific Reports
The aim of this study is to elucidate the disparities in survival and risk factors among different subtypes of liposarcoma, through analysis of epidemiological and prognostic data.
Jiaqi Zhao   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy